Well, itdoes look like the revised timetable (during 2nd quarter 2018/19) forannouncing a Japanese clinical licensing deal for Progenza will be missedunless an announcement is forthcoming tomorrow. However, based on the approachtaken in 2016 with the AGC manufacturing deal, RGS might choose to preface aProgenza licensing announcement with a trading halt - in which case wewould not see an announcement until early in the New Year.
Even ifthere is not a licensing announcement or a trading halt tomorrow or onWednesday, at the very least I would be expecting another licensing update tobe released to the market on one or the other of those days, so that patientand not so patient shareholders alike are put in the picture about the currentlicensing situation, why the revised timetable could not be met, andso as all shareholders can adjust their future expectations as may be required.
Whilewe're on the subject of announcements, it may be of interest that it's now morethan 6 weeks since the CEO reportedly told the journalist, Tim Boreham inrelation to either Cryoshot and/or Kvax, and/or RGS's relationship with one ofthe biggest vet pharmas in the world (not sure which was being referred to), that the company "mayhave something to say about this over the next month or so" (see BiotechDaily article from Friday 16/11/18).
zeno9
